Difference between revisions of "Eli Lilly and Company"

From Powerbase
Jump to: navigation, search
(corporate services)
(changed heading)
Line 122: Line 122:
 
Eli Lilly provided generous support for the <i>Expert Consensus Guideline Series: Treatment of Schizophrenia 1999</i> an initiative aiming at establishing uniform medication guidelines for schizophrenia<ref> Weibert, S.  [http://www.teenscreentruth.com/New_Freedom_Commission.html The Genesis of President Bush’s New Freedom Commission on Mental Health] Teenscreen Truth. Accessed 9th January 2008</ref>. It is reported that this was an initiative 'supported exclusively by 6 pharmaceutical companies: [[Eli Lilly and Company]], [[Janssen Pharmaceutica Inc.]], [[Novartis]] Pharmaceuticals Corporation, [[Ortho-McNeil Pharmaceutical]], [[Pfizer]] Inc. and [[Zeneca Pharmaceuticals]]' (now known as [[AstraZeneca]]).  [[Michael Hogan]] and [[Laurie Flynn]] were also involved in this initiative.
 
Eli Lilly provided generous support for the <i>Expert Consensus Guideline Series: Treatment of Schizophrenia 1999</i> an initiative aiming at establishing uniform medication guidelines for schizophrenia<ref> Weibert, S.  [http://www.teenscreentruth.com/New_Freedom_Commission.html The Genesis of President Bush’s New Freedom Commission on Mental Health] Teenscreen Truth. Accessed 9th January 2008</ref>. It is reported that this was an initiative 'supported exclusively by 6 pharmaceutical companies: [[Eli Lilly and Company]], [[Janssen Pharmaceutica Inc.]], [[Novartis]] Pharmaceuticals Corporation, [[Ortho-McNeil Pharmaceutical]], [[Pfizer]] Inc. and [[Zeneca Pharmaceuticals]]' (now known as [[AstraZeneca]]).  [[Michael Hogan]] and [[Laurie Flynn]] were also involved in this initiative.
  
==Corporate Services==
+
==Public Relations, Lobbying and Business Intelligence Firms==
 
In 2008, Eli Lilly is listed as a cleint for [[Business Insights]]<ref> Business Insights [http://globalbusinessinsights.com/content/rbhc0019m.pdf Patient Power: The shift towards more informed, more powerful consumers of drugs] Accessed 5th February 2008</ref>
 
In 2008, Eli Lilly is listed as a cleint for [[Business Insights]]<ref> Business Insights [http://globalbusinessinsights.com/content/rbhc0019m.pdf Patient Power: The shift towards more informed, more powerful consumers of drugs] Accessed 5th February 2008</ref>
  

Revision as of 14:55, 12 February 2008

People

Board of Directors

Eli Lilly and Company list their Board of Directors for 2007 as[1]...

  • Alfred G Gilman - Gilman's biography[9] reports that he joined Eli Lilly in 1995. Gilman is also Executive Vice President for academic affairs and provost at the University of Texas Southwestern Medical Center at Dallas, where he also serves as regental professor of pharmacology and as Dean of Southwestern Medical School. He is a member of the board of directors of Regeneron Pharmaceuticals Inc.. Gilman previously served ten years with the University of Virginia in Charlottesville (commencing in 1971), where his positions included assistant, associate, and professor of pharmacology, and director of the medical scientist training program. He was also the editor of Goodman and Gilman's The Pharmacological Basis of Therapeutics from 1980–1990.

Executive Management

Eli Lilly and Company list their Executive Management for 2007 as comprising[15]...

Patient Groups

Eli Lilly and Company UK report their relationships with Patient Groups in 2006 as follows[16]...

In 2006, the Lilly Grants Committee has made the following grants:

Affiliations

Eli Lilly list some of their alliances with other organisations as follows[17]. The exact nature and timescales of the alliances are not disclosed.

Particia Martin, Executive Director of alliance management at Eli Lilly reported to Pharmaceutical Executive [18] that Lilly has been partnering for a long time and is involved in hundreds of alliances.

Eli Lilly provided generous support for the Expert Consensus Guideline Series: Treatment of Schizophrenia 1999 an initiative aiming at establishing uniform medication guidelines for schizophrenia[19]. It is reported that this was an initiative 'supported exclusively by 6 pharmaceutical companies: Eli Lilly and Company, Janssen Pharmaceutica Inc., Novartis Pharmaceuticals Corporation, Ortho-McNeil Pharmaceutical, Pfizer Inc. and Zeneca Pharmaceuticals' (now known as AstraZeneca). Michael Hogan and Laurie Flynn were also involved in this initiative.

Public Relations, Lobbying and Business Intelligence Firms

In 2008, Eli Lilly is listed as a cleint for Business Insights[20]

References

  1. Elli Lilly and Company Director Profiles Accessed 27th December 2007
  2. Eli Lilly and Company Sidney Taurel Accessed 31st January 2008
  3. Eli Lilly and Company Winifried Bischoff Accessed 31st January 2008
  4. Eli Lilly Company J Michael Cook Accessed 31st January 2008
  5. Eli Lilly and Company Martin S Feldstein Accessed 31st January 2008
  6. Eli Lilly and Company George M C Fisher Accessed 31st January 2008
  7. Clinton Presidential Centre President Names Members to Advisory Committee for Trade Policy Accessed 31st January 2008
  8. Eli Lilly and Company J Erik Fyrwald Accessed 31st January 2008
  9. Eli Lilly and Company Alfred G Gilman Accessed 31st January 2008
  10. Eli Lilly and Company Karen N Horn Accessed 31st January 2008
  11. Eli Lilly and Company John C Lechleiter Accessed 31st January 2008
  12. Eli Lilly and Company Ellen R Marram accessed 31st January 2008
  13. Eli Lilly and Company Franklin G Prendergast Accessed 31st January 2008
  14. Eli Lilly and Company Kathi P Seifert accessed 31st January 2008
  15. Eli Lilly and Company Executive Management Accessed 27th December 2007
  16. Eli Lilly and Company Patient Group Relationships Accessed 31st December 2007
  17. Eli Lilly and Company Alliances Accessed 31st December 2007
  18. Pharmaceutical Executive Biotech and Pharma - Why Alliances FailAccessed 31st December 2007
  19. Weibert, S. The Genesis of President Bush’s New Freedom Commission on Mental Health Teenscreen Truth. Accessed 9th January 2008
  20. Business Insights Patient Power: The shift towards more informed, more powerful consumers of drugs Accessed 5th February 2008